SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and manageable safety.
Alessandra Tedeschi, MD
Advertisement
Articles by Alessandra Tedeschi, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis
2
FDA Approves Palbociclib Plus Anti-HER2 and Endocrine Therapy as Maintenance in Breast Cancer
3
Gene Signature Predicts Anthracycline Benefit in HR+/HER2– Breast Cancer
4
Beyond KOMET-007: What’s Next for Ziftomenib in AML
5